<DOC>
	<DOCNO>NCT01723657</DOCNO>
	<brief_summary>The AML-03 regimen investigate addition G-CSF priming induction consolidation chemotherapy administrate previous AML-99 trial ( NCT01716793 ) refine risk-stratification base biological characterization also AML-03 trial incorporates novel approach hematopoietic stem cell transplantation : Mylotarg™ `` vivo purge '' autograft , extends unrelated volunteer donor allotransplants high-risk patient , introduces reduce intensity conditioning patient elder age ( 50 year old ) . The aims modification analyse eficacy toxicity induction consolidation therapy analyse disease free survival patient achieve complete response follow risk adjust therapy .</brief_summary>
	<brief_title>Risk Adapted Treatment Primary Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Induction chemotherapy : idarubicin ( 12mg/m2/day intravenous , day 1 , 3 5 ) , intermediate-dose cytarabine ( 500mg/m2/12h , intravenous , day 1 , 3 5 ) etoposide ( 100mg/m2/day , intravenous , day 1 3 ) AML-99 trial ( NCT01716793 ) , addition subcutaneous G-CSF day 0 last day chemotherapy . This induction therapy repeat complete remission ( CR ) achieve first course treatment . Consolidation therapy ( AML-99 trial ) : mitoxantrone ( 12mg/m2/day , intravenous , day 4 6 ) intermediate-dose cytarabine ( 500mg/m2/12h day 1 6 ) . Risk-stratification accord cytogenetics , course CR availability HLA-identical sibling : - Patients favorable cytogenetics group [ ( 8 ; 21 ) , inv ( 16 ) ( 16 ; 16 ) ] Leukocyte index &lt; 20 diagnosis ( LI=white blood cell count ( WBC ) x ( blast bone marrow/100 ) treat one course high-dose cytarabine ( 3g/m2/12h , intravenous , day 1 , 3 5 ) , case LI &gt; 20 diagnosis intention perform autologous peripheral blood stem cell ( PBSC ) transplantation . - Patients intermediate risk group , normal karyotype , single course induction chemotherapy achieve CR , absence adverse molecular feature ( FLT3-ITD MLL-PTD ) low minimal residual disease level consolidation ( MRD &lt; 0,1 % ) receive autologous PBSC transplant , regardless HLA-identical sibling . - The remain patient define high-risk patient treat allogeneic stem cell transplantation . Depending age , patient HLA-identical sibling donor , age 50 year old perform conventional conditioning therapy positive selection CD34+ , old patient receive reduce intensity condition regimen . - Very high risk patient without sibling allocate unrelated donor ( 9-10/10 ) . Patients adverse cytogenetics and/or FLT3-ITD without adequate donor receive Mylotarg™ `` vivo purge '' follow autologous PBSC transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Patients newly diagnose AML , classify use OMS criterion . Patients 70 year old young . Patients previously treat AML chemotherapy different hidroxiurea . Acute promyelocytic leukemia ( 15 ; 17 ) . Cronic mieloid leukemia blastic crisis . Leukemias appear myeloproliferative process . Leukemias survive myelodysplasic syndrome 6 month evolution . Presence neoplasic disease activity . Secondary AML appear cure malignant disease ( instance , Hodgking disease ) , still expose alkilant agent radiation . Abnormal renal hepatic function creatinin and/or bilirrubine 2 time higher normal threshold , except alteration attribute leukemia . Patient ejection fraction 40 % , symptomatic cardiac deficiency . Patients neurological concomitant psychiatric disease . Positivity HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Acute</keyword>
	<keyword>Young</keyword>
	<keyword>CETLAM</keyword>
</DOC>